The level of impact of ADE (Antibody-Dependent Enhancement) on morbidity and mortality in humans vaccinated against Omicron COULD BE similar to that observed in non-vaccinated chickens contracting Marek.
Similarities and differences:
The Marek vaccines may have been protective effect against disease but vaccination against Marek disease using imperfect/ leaky vaccines leads to increased viral virulence (i.e., enhanced morbidity and mortality rate) in unvaccinated chicken.
Geert Vanden Bossche has been predicting that mass vaccination of humans with imperfect/ leaky C-19 vaccines against Omicron will result in high rates of morbidity and mortality from SARS-CoV-2 in the VERY VACCINEES, especially if treatment protocols keep being disapproved.
So the healthy unvaccinated will now begin getting infected due to mass vaccination but Geert believes the vaccinated will pay a heavier price especially if early treatment is suppressed.
Symptoms of Marek disease in chicken are, of course, very different from those provoked by an enhanced form of C-19 disease in humans.
- Wherever you are vaccinated or not many doctors are saying that it is critical that people are not found deficient in Vitamin-D3.
About Geert Vanden Bosche
Geert Vanden Bossche received his DVM from the University of Ghent, Belgium, and his PhD degree in Virology from the University of Hohenheim, Germany. He held adjunct faculty appointments at universities in Belgium and Germany. After his career in Academia, Geert joined several vaccine companies (GSK Biologicals, Novartis Vaccines, Solvay Biologicals) to serve various roles in vaccine R&D as well as in late vaccine development.
Geert then moved on to join the Bill & Melinda Gates Foundation’s Global Health Discovery team in Seattle (USA) as Senior Program Officer; he then worked with the Global Alliance for Vaccines and Immunization (GAVI) in Geneva as Senior Ebola Program Manager. At GAVI he tracked efforts to develop an Ebola vaccine. He also represented GAVI in fora with other partners, including WHO, to review progress on the fight against Ebola and to build plans for global pandemic preparedness.
Back in 2015, Geert scrutinized and questioned the safety of the Ebola vaccine that was used in ring vaccination trials conducted by WHO in Guinea. His critical scientific analysis and report on the data published by WHO in the Lancet in 2015 was sent to all international health and regulatory authorities involved in the Ebola vaccination program. After working for GAVI, Geert joined the German Center for Infection Research in Cologne as Head of the Vaccine Development Office. He is at present primarily serving as a Biotech / Vaccine consultant while also conducting his own research on Natural Killer cell-based vaccines.